🇺🇸 FDA
Patent

US 11013740

Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

granted A61KA61K31/505A61K33/24

Quick answer

US patent 11013740 (Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy) held by The Board of Regents of the University of Texas System expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/505, A61K33/24, A61K33/243